rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

John Thomas

Director

Company insider

Files Form 4 as: Director, Genelux.

Every Form 4 they filed

In numbers

Trades disclosed
29
Buys
1
Sells
7
Bought
$0
Sold
$513K
Companies
1
Companies where not an officer
1
First trade
30 Jan 2023
Last trade
16 Jun 2026
Last filed
18 Jun 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
GNLX GeneluxDirector · Biotechnology · last 16 Jun 20261 buy · 7 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
10Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
16 Jun 2026filed 18 Jun 2026GNLX GeneluxBiotechnologySEC FORM 4 Code A—28,409 at $0.00filing
16 Jun 2026filed 18 Jun 2026GNLX Geneluxoption or derivative · BiotechnologySEC FORM 4 Code A—31,566 at $0.00filing
16 Jun 2026filed 18 Jun 2026GNLX Geneluxoption or derivative · BiotechnologySEC FORM 4 Code A—31,566 at $0.00filing
16 Jun 2026filed 18 Jun 2026GNLX GeneluxBiotechnologySEC FORM 4 Code A—28,409 at $0.00filing
1 Jun 2026filed 2 Jun 2026GNLX GeneluxBiotechnologySEC FORM 4 Sold$30K10,000 at $2.98filing
1 Jun 2026filed 2 Jun 2026GNLX GeneluxBiotechnologySEC FORM 4 Sold$30K10,000 at $2.98filing
2 Mar 2026filed 3 Mar 2026GNLX GeneluxBiotechnologySEC FORM 4 Sold$29K10,000 at $2.90filing
2 Mar 2026filed 3 Mar 2026GNLX GeneluxBiotechnologySEC FORM 4 Sold$29K10,000 at $2.90filing
1 Dec 2025filed 2 Dec 2025GNLX GeneluxBiotechnologySEC FORM 4 Sold$50K10,000 at $5.00filing
27 Aug 2025filed 29 Aug 2025GNLX Geneluxoption or derivative · BiotechnologySEC FORM 4 Code A—28,576 at $0.00filing
27 Aug 2025filed 29 Aug 2025GNLX GeneluxBiotechnologySEC FORM 4 Code A—22,283 at $0.00filing
6 Jun 2025filed 24 Jun 2025GNLX GeneluxBiotechnologySEC FORM 4 Code G—25,000 at $0.00filing
1 Aug 2024filed 31 Dec 2024GNLX Geneluxoption or derivative · BiotechnologySEC FORM 4 Code A—50,469 at $0.00filing
1 Aug 2024filed 5 Aug 2024GNLX Geneluxoption or derivative · BiotechnologySEC FORM 4 Code A—50,469 at $0.00filing
1 Aug 2024filed 5 Aug 2024GNLX GeneluxBiotechnologySEC FORM 4 Code A—39,541 at $0.00filing
29 May 2024filed 7 Jun 2024GNLX Geneluxoption or derivative · BiotechnologySEC FORM 4 Code P—2,500filing
29 May 2024filed 7 Jun 2024GNLX GeneluxBiotechnologySEC FORM 4 Bought—2,500filing
13 Dec 2023filed 14 Dec 2023GNLX GeneluxBiotechnologySEC FORM 4 Sold$94K7,073 at $13.23filing
13 Dec 2023filed 14 Dec 2023GNLX GeneluxBiotechnologySEC FORM 4 Sold$27K1,927 at $13.93filing
16 Oct 2023filed 16 Oct 2023GNLX GeneluxBiotechnologySEC FORM 4 Sold$50K2,452 at $20.50filing

News

Head-To-Head Analysis: Foghorn Therapeutics (NASDAQ:FHTX) vs. Genelux (NASDAQ:GNLX)GNLX · themarketsdaily.com · 11 Oct 2026

0 headlines in the last 90 days name John Thomas; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care8

Buys in green, sells in red, by the company’s sector.

Related people

Yong YuChief Scientific Officer · Chief Scientific Officer at Genelux, filing Form 4 there in the last year
Joseph CappelloChief Technical Officer · Chief Technical Officer at Genelux, filing Form 4 there in the last year
Thomas ZindrickPresident and CEO · President and CEO at Genelux, filing Form 4 there in the last year
John W. SmitherDirector · Director at Genelux, filing Form 4 there in the last year
Matthew PulisicChief Financial Officer · Chief Financial Officer at Genelux, filing Form 4 there in the last year